Avience Biomedicals IPO Review: Profit Surges 238%, But Don’t Miss This Key Risk!
Avience Biomedicals, a new player in the Indian healthcare and diagnostics sector, is set to launch its IPO from June 18 to June 22, 2026, with a price band ranging from INR 196 to INR 208 per share, aiming to raise approximately INR 28.49 to INR 30.24 crore. The issue consists entirely of a fresh equity offering, with a minimum bid of 1,200 shares. Approximately 35% of the net offer is allocated to retail investors, indicating a focus on engaging the retail segment. The company’s move to list on the NSE EMERGE underscores its ambitions to utilize the funds for significant capital expansion, including the construction of a new production facility at the Medical Device Park in YEIDA, which aims to enhance its production capabilities and achieve compliance with global standards such as WHO and US FDA.
Market sentiment surrounding the Avience Biomedicals IPO appears cautiously optimistic, driven by the company’s strategic shift from low-margin trading to high-margin manufacturing operations in the in-vitro diagnostics and medical devices space. The healthy growth trajectory reflected in its financials—particularly the substantial increase in net profit margins and return ratios—paints a positive picture for potential investors. The notable decrease in reliance on imports, with domestic sourcing soaring, is also likely to resonate well with the “Make in India” narrative, further attracting investor interest. However, there are pressing concerns regarding supplier and customer concentration that could impact operational stability, which investors should factor into their decision-making process.
For Indian investors, the Avience Biomedicals IPO represents an enticing opportunity to invest in a company poised for growth in an expanding sector. The anticipated shift towards high-margin manufacturing is expected to enhance profitability, as evidenced by the increasing contribution of manufacturing revenue to the overall revenue mix. However, investors must weigh the inherent risks carefully, notably supplier concentration and the company’s heavy dependence on a limited geographical and customer base, which could expose them to localized disruptions. Overall, the IPO may serve as a promising avenue for those aligning with the growth story of domestic manufacturing in India, but due diligence on the associated risks is essential.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)